NCT04649723View on ClinicalTrials.gov

Drug-Drug Interaction of SHR1459 With a Strong CYP3A Index Inducer (Rifampicin)

PHASE1CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

November 24, 2020

Primary Completion Date

December 14, 2020

Study Completion Date

December 14, 2020

Conditions
Healthy Subjects, Drug-drug Interaction, Pharmacokinetics, SHR1459
Interventions
DRUG

Rifampin

single oral dose, 600 mg, fasted.

DRUG

SHR1459

single oral dose, 200 mg, fasted.

Trial Locations (1)

201203

Jiangsu HengRui Medicine Co., Ltd., Shanghai

All Listed Sponsors
lead

Jiangsu HengRui Medicine Co., Ltd.

INDUSTRY

NCT04649723 - Drug-Drug Interaction of SHR1459 With a Strong CYP3A Index Inducer (Rifampicin) | Biotech Hunter | Biotech Hunter